AtaiBeckley Insiders Sold Before $6.75 Lilly Bid
AtaiBeckley has agreed to a $6.75-per-share cash acquisition by Eli Lilly, with Reuters pegging total value at up to $3.8 billion, as shares trade at $7.26 reflecting CVR optionality. Three insiders s
AtaiBeckley Backs $6.75 Lilly Deal as Insiders Sold Lower
NEW YORK, August 10 —
AtaiBeckley Inc. (ATAI) has agreed to a $6.75-per-share cash sale to Eli Lilly, valuing the psychedelic-drug developer at up to $3.8 billion per Reuters. In the six weeks before the board put that price on the table, three insiders collectively sold $940,000 worth of shares at $4.51 to $5.00.
- Lilly deal: $6.75 cash per share plus CVR; Reuters pegged total value at up to $3.8 billion.
- ATAI trades at $7.26, above the deal price; the premium reflects CVR value or deal-close uncertainty.
- Three insiders sold $940,000 in shares at $4.51 to $5.00 before the July 16 SEC deal filings.
The Selling Pattern
COO Gerd Kochendoerfer sold 50,000 shares at $5.00 on June 26; CMO Kevin James Craig sold 42,579 at $4.51 the day before; and Robert Hershberg, the largest seller, unloaded 100,000 shares at $4.96 on July 7. Lilly's offer came in 35 to 50 percent above what each insider accepted. Hershberg's trade came nine days before AtaiBeckley filed ten supplemental proxy statements and an 8-K on July 16, filings consistent with soliciting a shareholder vote on a merger. Net insider activity over the 90-day period: $940,000 in sales, zero purchases.
Why Option Mechanics Don't Close the Case
Each seller exercised stock options immediately before their open-market sale: Craig at $1.50 and $1.18 per share, Kochendoerfer at $1.60, and Hershberg at $1.35. Exercise-and-sell is standard option monetization, not inherently suspicious. AtaiBeckley develops intranasal, oral, and film-based psychedelic compounds, led by BPL-003 for treatment-resistant depression and alcohol use disorder, with zero revenue and negative $106 million in operating cash flow. A company that missed EPS estimates by over 1,400% last quarter gives plausible reason to lock in gains at $4.50. Whether that rationale survives the proximity to a deal that put the offer price on the table nine days later is the open question.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ATAI | $2.7B | n/a | +83.1% |
| GHRS | $2.0B | n/a | +156.5% |
| CMPS | $1.8B | n/a | +212.0% |
| HELP | $620M | n/a | +59.9% |
| IXHL | $39M | n/a | -76.5% |
| ABSI | $1.5B | n/a | +213.3% |
What the CVR Gap Signals
ATAI trades at $7.26, above the deal price, with the gap reflecting whatever value the market assigns to the CVR. Analyst consensus had pegged ATAI at $9.59 before the announcement, suggesting the street already embedded significant pipeline optionality above the base price. Cathie Wood called the $3.8 billion transaction a "well-deserved" return for shareholders, per TradingView. The shareholder vote is the next formal checkpoint; how regulators assess the June-July selling window against the merger timeline is the parallel process worth tracking. For the underlying numbers, run the free AtaiBeckley Inc. deep-dive → /stock/atai, or stress-test pipeline assumptions in the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is the AtaiBeckley Eli Lilly deal price?
Eli Lilly agreed to acquire AtaiBeckley at $6.75 per share in cash plus a contingent value right. Reuters pegged the total transaction value at up to $3.8 billion. AtaiBeckley shares were trading at $7.26 at the time of the report, above the base deal price.
Did ATAI insiders sell shares before the Lilly deal?
Three insiders sold a combined $940,000 in shares at prices between $4.51 and $5.00 in the six weeks before the deal was publicly filed. COO Gerd Kochendoerfer, CMO Kevin James Craig, and Robert Hershberg all sold at prices 35 to 50 percent below Lilly's $6.75 offer.
Why does ATAI trade above the $6.75 deal price?
AtaiBeckley shares trade at $7.26, above the $6.75 deal price, with the gap reflecting whatever value the market assigns to the CVR included in the deal. Analyst consensus had pegged ATAI at $9.59 before the announcement, suggesting the street had already embedded meaningful pipeline optionality above the base price.
What drugs does AtaiBeckley develop?
AtaiBeckley develops intranasal, oral, and film-based psychedelic compounds, with BPL-003 as its lead program targeting treatment-resistant depression and alcohol use disorder. The company reports zero revenue and negative $106 million in operating cash flow.
What does ATAI's CVR mean for shareholders?
The deal pairs a $6.75 cash payment per share with a contingent value right, with Reuters pegging total value at up to $3.8 billion. AtaiBeckley shares trade at $7.26, above the base deal price, with the premium reflecting whatever value the market assigns to the CVR.
AtaiBeckley's board has endorsed a $6.75-per-share cash sale to Eli Lilly with additional contingent value right upside — but the company's COO, CMO, and a major insider collectively sold $940,000 in shares at $4.51 to $5.00 in the six weeks before that price was put on the table.